Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI119511

Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100.

M M Véniant, V Pierotti, D Newland, C M Cham, D A Sanan, R L Walzem, and S G Young

Gladstone Institute of Cardiovascular Disease, San Francisco, California 94141-9100, USA. murielle_veniantGICD@quickmail.ucsf.edu

Find articles by Véniant, M. in: JCI | PubMed | Google Scholar

Gladstone Institute of Cardiovascular Disease, San Francisco, California 94141-9100, USA. murielle_veniantGICD@quickmail.ucsf.edu

Find articles by Pierotti, V. in: JCI | PubMed | Google Scholar

Gladstone Institute of Cardiovascular Disease, San Francisco, California 94141-9100, USA. murielle_veniantGICD@quickmail.ucsf.edu

Find articles by Newland, D. in: JCI | PubMed | Google Scholar

Gladstone Institute of Cardiovascular Disease, San Francisco, California 94141-9100, USA. murielle_veniantGICD@quickmail.ucsf.edu

Find articles by Cham, C. in: JCI | PubMed | Google Scholar

Gladstone Institute of Cardiovascular Disease, San Francisco, California 94141-9100, USA. murielle_veniantGICD@quickmail.ucsf.edu

Find articles by Sanan, D. in: JCI | PubMed | Google Scholar

Gladstone Institute of Cardiovascular Disease, San Francisco, California 94141-9100, USA. murielle_veniantGICD@quickmail.ucsf.edu

Find articles by Walzem, R. in: JCI | PubMed | Google Scholar

Gladstone Institute of Cardiovascular Disease, San Francisco, California 94141-9100, USA. murielle_veniantGICD@quickmail.ucsf.edu

Find articles by Young, S. in: JCI | PubMed | Google Scholar

Published July 1, 1997 - More info

Published in Volume 100, Issue 1 on July 1, 1997
J Clin Invest. 1997;100(1):180–188. https://doi.org/10.1172/JCI119511.
© 1997 The American Society for Clinical Investigation
Published July 1, 1997 - Version history
View PDF
Abstract

All classes of lipoproteins considered to be atherogenic contain apo-B100 or apo-B48. However, there is a distinct paucity of data regarding whether lipoproteins containing apo-B48 or apo-B100 differ in their intrinsic ability to promote the development of atherosclerosis. To address this issue, we compared the extent of atherosclerosis in three groups of animals: apo-E-deficient mice (apo-B+/+apo-E-/-) and apo-E-deficient mice that synthesize exclusively either apo-B48 (apo-B48/48apo-E-/-) or apo-B100 (apo-B100/100apo-E-/-). Mice (n = 25 in each group) were fed a chow diet for 200 days, and plasma lipid levels were assessed throughout the study. Compared with the levels in apo-B+/+apo-E-/- mice, the total plasma cholesterol levels were higher in the apo-B48/48apo-E-/- mice and were lower in the apo-B100/100apo-E-/- mice. However, the ranges of cholesterol levels in the three groups overlapped. Compared with those in the apo-B+/+apo-E-/- mice, atherosclerotic lesions were more extensive in the apo-B48/48apo-E-/- mice and less extensive in the apo-B100/100apo-E-/- mice. Once again, however, there was overlap among the three groups. The extent of atherosclerosis in each group of mice correlated significantly with plasma cholesterol levels. In mice from different groups that had similar cholesterol levels, the extent of atherosclerosis was quite similar. Thus, susceptibility to atherosclerosis was dependent on total cholesterol levels. Whether mice synthesized apo-B48 or apo-B100 did not appear to have an independent effect on susceptibility to atherosclerosis.

Version history
  • Version 1 (July 1, 1997): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts